Guardant Health (NASDAQ:GH) Insider Terilyn Monroe Sells 46,300 Shares

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 46,300 shares of Guardant Health stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the completion of the sale, the insider owned 22,979 shares of the company’s stock, valued at $3,794,292.48. This trade represents a 66.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Guardant Health Price Performance

Guardant Health stock traded down $5.57 during mid-day trading on Thursday, reaching $159.54. 2,799,378 shares of the company traded hands, compared to its average volume of 2,011,409. Guardant Health, Inc. has a fifty-two week low of $53.40 and a fifty-two week high of $176.58. The company has a market capitalization of $21.41 billion, a price-to-earnings ratio of -45.71 and a beta of 1.60. The firm’s fifty day moving average is $149.77 and its two-hundred day moving average is $116.59.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GH. TD Cowen upped their target price on Guardant Health from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Stephens boosted their price target on Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Sanford C. Bernstein increased their price objective on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, July 2nd. Canaccord Genuity Group lifted their target price on Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Finally, Guggenheim upped their target price on Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Guardant Health currently has an average rating of “Moderate Buy” and an average price target of $183.78.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Guardant Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock worth $1,242,101,000 after purchasing an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after purchasing an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Guardant Health by 14.9% in the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after purchasing an additional 435,232 shares during the period. Geode Capital Management LLC lifted its stake in shares of Guardant Health by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after purchasing an additional 277,001 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its holdings in Guardant Health by 3.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after buying an additional 72,162 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.